📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-25 21:00
0 analysed today
0
Today
133,620
All-time analysed
40,132
Positive
6,284
Negative
79,384
Neutral
7,752
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
36 announcements match the current filters (relevance ≥ 5).
Honasa Calls Off Proposed Acquisition of 58% Stake in Fluence Pharma
Honasa Consumer Limited has called off its proposed acquisition of a 58% equity stake in Fluence Pharma Private Limited as of August 25, 2026. The deal, originally announced on June 23, 2026, was terminated due to the non-fulfilment of conditions precedent outlined in the Share Purchase Agreement. Honasa stated it remains committed to its nutraceutical strategy and will pursue alternative organic and inorganic routes.
Confidence: HIGH
What changedHonasa has formally terminated its Share Purchase Agreement to acquire a 58% stake in Fluence Pharma.
Why it mattersPauses immediate inorganic entry into the nutraceuticals segment, preserving capital while requiring the company to seek new pathways for category expansion.
Proposed stake: 58%Termination date: August 25, 2026Original agreement date: June 23, 2026Honasa TTM Revenue: Rs 2527 Cr
📅 Short termLimited operational impact as the deal was pending closing conditions and had not been consolidated into financials.
📈 Long termExpansion into nutraceuticals will now depend on greenfield product launches or new M&A targets.
⚠ Risk flags
- Potential delay in time-to-market for the planned nutraceutical product portfolio
Key Highlights
Terminated the proposed acquisition of a 58% equity stake in Fluence Pharma Private Limited on August 25, 2026.
Decision driven by non-fulfilment of closing conditions specified under the Share Purchase Agreement.
Follows initial disclosure regarding the proposed transaction dated June 23, 2026.
Management reaffirmed commitment to expanding into the nutraceutical category via alternate opportunities.
👀 What to Watch
Monitor management commentary in upcoming quarterly calls regarding alternative organic or inorganic routes to build out the nutraceutical vertical.
Honasa Reports Q1 FY27: Revenue Up 32%, EBITDA at ₹110 Cr with 30.5% Volume Growth
Honasa Consumer released its Q1 FY27 earnings call transcript, highlighting a 32% YoY revenue growth supported by 30.5% volume expansion. Quarterly EBITDA reached ~₹110 Cr with PAT at ₹90 Cr, while generating ₹83 Cr in cash flow during the quarter. Focus categories contributed ~85% of total revenue, expanding by 35%+, while offline channels showed strong momentum with General Trade secondary sales and Modern Trade offtakes both growing 40%+. Management reiterated its 5-year target of expanding EBITDA margins by 100–150 bps annually towards a 15% target.
Confidence: HIGH
What changedSubmission of the formal transcript of the Q1 FY27 earnings conference call held on August 13, 2026.
Why it mattersDemonstrates healthy volume-led growth acceleration, successful offline channel restructuring, and steady expansion across hero product franchises.
Volume growth: 30.5%Q1 EBITDA: INR 110 croresQ1 PAT: INR 90 croresCash generated in Q: INR 83 croresFocus category revenue share: almost 85%5-year annual EBITDA margin expansion target: 100 basis points to 150 basis points
📅 Short termReaffirms strong execution in core categories, though management highlighted that Q2 scale may face typical seasonal moderations compared to Q1.
📈 Long termSupports the thesis of expanding younger brands and offline distribution reaching critical scale to sustain double-digit top-line growth and margin expansion towards 15%.
⚠ Risk flags
- Reinvestment of margins into aggressive A&P spending for growth
- Seasonality fluctuations between summer and winter quarters
Key Highlights
Revenue grew 32% YoY in Q1 FY27, backed by 30.5% volume growth
EBITDA reached ~₹110 Cr (normalized margin around ~12% excluding one-time items) and PAT stood at ₹90 Cr
Generated ₹83 Cr of cash during the quarter while maintaining negative working capital
Focus categories grew 35%+ YoY and represented ~85% of Q1 FY27 revenue
Offline traction strengthened with 40%+ growth in General Trade secondary sales and Modern Trade offtakes
👀 What to Watch
Track the sustainability of offline general trade growth (Project Neev) and margin progression in seasonally softer quarters like Q2.
₹3 Final Dividend: Honasa Consumer Sets August 28 as Record Date for FY26
Honasa Consumer Limited has announced its 10th Annual General Meeting (AGM) for September 28, 2026. The company has declared a final dividend of ₹3 per equity share for FY26, which represents a payout of approximately 48.8% of its TTM EPS of ₹6.15. The record date for determining dividend eligibility is August 28, 2026. This follows a year where the company reported TTM revenue of ₹2,355 Cr and a PAT of ₹195 Cr.
Confidence: HIGH
What changedThe company has formalized the dates for its 10th AGM and the record date for the final dividend payment for FY26.
Why it mattersThe dividend confirms the company's ability to return cash to shareholders following a profitable FY26 (PAT of ₹195 Cr) and provides a timeline for the annual shareholder interaction.
Final Dividend: ₹3 per equity shareRecord Date: August 28, 2026Dividend Yield: 0.63%Dividend Payout (vs TTM EPS): ~48.8%AGM Date: September 28, 2026
📅 Short termThe stock may see mild positive sentiment leading up to the record date of August 28 as investors seek to qualify for the dividend.
📈 Long termLimited structural impact as this is a routine corporate action, though it reflects a maturing financial profile with consistent payouts.
Key Highlights
Final dividend of ₹3 per equity share declared for the financial year 2025-26
Record date for dividend eligibility fixed as Friday, August 28, 2026
10th Annual General Meeting scheduled for Monday, September 28, 2026
Cut-off date for e-voting eligibility set for Monday, September 21, 2026
👀 What to Watch
Investors should note the record date of August 28 to be eligible for the dividend and watch the upcoming AGM for management updates on the 'Focus Categories' growth strategy.
₹3 Final Dividend: Honasa Sets August 28, 2026, as Record Date
Honasa Consumer has fixed August 28, 2026, as the record date for a final dividend of ₹3 per equity share for FY 2025-26. This dividend represents a payout of approximately 48.8% of the company's TTM EPS of ₹6.15. The distribution is subject to shareholder approval at the 10th Annual General Meeting (AGM) scheduled for September 28, 2026. At the current market price of ₹484.7, the dividend yield is approximately 0.62%.
Confidence: HIGH
What changedThe company has established the specific timeline for its FY26 final dividend payment and its 10th Annual General Meeting.
Why it mattersThe dividend confirms the company's transition to consistent profitability (FY26 PAT of ₹195 Cr) and its commitment to returning capital to shareholders while maintaining a growth-focused capital structure.
Final Dividend: ₹3 per shareDividend Yield: ~0.62%Payout Ratio (vs TTM EPS): ~48.8%Record Date: August 28, 2026AGM Date: September 28, 2026
📅 Short termThe stock may experience mild positive sentiment and volume as the record date approaches, though the modest yield is unlikely to drive significant price action.
📈 Long termLimited; while the dividend is a positive sign of maturity, the long-term value remains tied to the company's ability to scale younger brands like The Derma Co and Aqualogica.
Key Highlights
Final dividend declared at ₹3 per equity share for the financial year 2025-26
Record date for determining dividend eligibility is Friday, August 28, 2026
10th Annual General Meeting (AGM) to be held on Monday, September 28, 2026
Cut-off date for e-voting eligibility is Monday, September 21, 2026
Dividend payout ratio stands at ~48.8% relative to TTM EPS of ₹6.15
👀 What to Watch
Investors seeking the dividend must hold shares prior to the ex-dividend date (typically one business day before the August 28 record date). Monitor the upcoming Annual Report for updates on the 'Project Neev' offline expansion and the integration of the Reginald Men acquisition.
Rs 785 Cr Revenue: Honasa Delivers Record Q1 FY27 with 32% Growth and 2x EBITDA
Honasa Consumer reported its highest-ever quarterly performance in Q1 FY27, with revenue reaching Rs 785 Cr, a 31.8% YoY increase. Profitability saw a sharp uptick as EBITDA more than doubled to Rs 110 Cr, representing a 14.1% margin compared to previous levels. The company successfully scaled 'The Derma Co.' to a Rs 1,000 Cr Annual Sustainable Revenue (ARR) milestone, making it their second brand to reach this scale. Offline expansion remains aggressive, with outlet coverage reaching approximately 3 lakh retail points and growing at 40%+ in General and Modern Trade.
Confidence: HIGH
What changedHonasa has moved past the inventory recalibration issues of FY25 (Project Neev) to deliver record quarterly revenue and profit, driven by multi-brand scaling and offline expansion.
Why it mattersThe results validate Honasa's ability to build multiple large-scale brands (two brands now at Rs 1,000 Cr+ ARR) and improve margins through premiumization and operating leverage as younger brands enter the 'Teens EBITDA club'.
Q1 FY27 Revenue: Rs 785 CrQ1 Revenue vs TTM Revenue: ~33.3%Q1 EBITDA: Rs 110 CrQ1 PAT: Rs 90 CrEBITDA Margin: 14.1%The Derma Co. ARR: Rs 1,000 Cr
📅 Short termThe stock is likely to react positively to the significant EBITDA beat and the milestone achievement of The Derma Co. reaching Rs 1,000 Cr ARR.
📈 Long termThe company is structurally evolving into a diversified BPC player with a proven playbook for scaling digital-first brands into omnichannel leaders, though high valuation (P/E 78.8) remains a factor.
⚠ Risk flags
- High valuation multiples
- Execution risk in new categories like fragrances (FIKN)
- Intense competition in the digital-first BPC space
Key Highlights
Quarterly revenue reached an all-time high of Rs 785 Cr, growing 31.8% YoY
EBITDA more than doubled YoY to Rs 110 Cr with a margin of 14.1%
The Derma Co. crossed the Rs 1,000 Cr NSV ARR milestone
Offline distribution expanded to ~3 lakh FMCG retail outlets with 40%+ growth in GT and MT
BTM Ventures crossed Rs 150 Cr ARR, growing over 2x since its acquisition
👀 What to Watch
Investors should monitor the sustainability of the 14.1% EBITDA margin in upcoming quarters and the traction of the newly launched fragrance brand 'FIKN'. The successful scaling of The Derma Co. suggests the 'House of Brands' strategy is effectively reducing reliance on the flagship Mamaearth brand.
116.5% YoY PAT Growth: Honasa Reports Highest Ever Quarterly Revenue of ₹785 Cr (LFL)
Honasa Consumer reported a robust Q1 FY27 with Like-for-Like (LFL) revenue growing 31.8% YoY to ₹785 Cr, representing approximately 33% of its TTM revenue. EBITDA surged 140.7% YoY to ₹110 Cr, with LFL margins expanding significantly to 14.1% from 7.7% in the previous year. The growth was volume-led (30.5% UVG) and supported by The Derma Co reaching a ₹1,000 Cr Annual Revenue Run Rate (ARR). Profit After Tax (PAT) more than doubled to ₹90 Cr, driven by scale-led leverage and a shift toward high-margin focus categories.
Confidence: HIGH
What changedHonasa has achieved a significant margin breakout to 14.1% (LFL) while maintaining 30%+ volume growth, moving beyond its historical single-digit margin profile.
Why it mattersThe results validate the 'house of brands' strategy, showing that younger brands like The Derma Co can reach ₹1,000 Cr scale and contribute to group profitability alongside the flagship Mamaearth.
LFL Revenue (Q1 FY27): ₹785 CrPAT Growth (YoY): 116.5%EBITDA Margin (LFL): 14.1%The Derma Co ARR: ₹1,000 CrUnderlying Volume Growth: 30.5%Flipkart Settlement Revenue Impact: ₹29 Cr
📅 Short termThe stock is likely to react positively to the record quarterly revenue and the substantial expansion in EBITDA margins.
📈 Long termStructural growth remains strong as the company successfully scales multiple brands and expands its offline footprint to 3 lakh outlets, reducing digital-only dependency.
⚠ Risk flags
- High advertising and promotion (A&P) spend at 31.8% of revenue
- Accounting-led revenue fluctuations due to marketplace settlement changes
- Intense competition in the premium face-care segment
Key Highlights
Like-for-Like (LFL) revenue grew 31.8% YoY to ₹785 Cr, adjusted for a ₹29 Cr accounting change in Flipkart settlement terms.
EBITDA margins expanded by 636 bps YoY to 14.1% on an LFL basis, driven by B2B channel mix and scale leverage.
The Derma Co achieved a milestone ₹1,000 Cr Net Sales Value (NSV) Annual Revenue Run Rate (ARR).
Focus categories contribution to total revenue expanded by 450 bps YoY to reach 85%+ in Q1 FY27.
Offline distribution reach expanded to approximately 3 lakh retail outlets as of June 2026.
👀 What to Watch
Investors should monitor the sustainability of the 14%+ EBITDA margin and the execution of the 'Project Neev' offline expansion, as well as the integration of the Reginald Men brand which has doubled revenue since acquisition.
Rs 25.5 Cr Legal Award Win; Honasa Approves Fluence Pharma M&A and Q1 Results
Honasa Consumer reported its Q1 FY27 results alongside a significant legal victory where an arbitral tribunal awarded the company AED 9.92 million (~Rs 25.53 crore) in damages from its former UAE distributor, RSM. The board also progressed with the acquisition of a 58% majority stake in Fluence Pharma and the incorporation of a new nutraceuticals subsidiary, Honasa Health Private Limited. A final dividend of Rs 3 per share was confirmed, subject to shareholder approval. Additionally, the company allotted 654,422 equity shares following ESOP exercises during the quarter.
Confidence: HIGH
What changedThe company successfully resolved a major international distribution dispute and formalized its strategic entry into the nutraceuticals and pharma-grade BPC segments.
Why it mattersThe legal award represents a one-time gain equivalent to approximately 13% of TTM PAT, while the M&A and new subsidiary signal a diversification strategy beyond core beauty products into high-margin wellness categories.
Legal Award Value: Rs 255.36 millionLegal Award vs TTM PAT: ~13.1%Dividend per share: Rs 3Fluence Pharma Stake: 58%ESOP Allotment: 654,422 shares
📅 Short termThe stock is likely to see positive sentiment driven by the legal victory and the dividend recommendation, providing a buffer to the quarterly earnings performance.
📈 Long termStructural expansion into nutraceuticals and specialized pharma-BPC through Fluence Pharma could expand the company's addressable market and improve long-term margin profiles.
⚠ Risk flags
- Execution risk in the new nutraceuticals vertical
- Potential for further legal appeals by the distributor in international courts
- Integration risks associated with the Fluence Pharma acquisition
Key Highlights
Arbitral award of Rs 25.53 crore (AED 9.92 million) granted in favor of the company against RSM for breach of distribution agreement.
Acquisition of 58% majority stake in Fluence Pharma approved, with the remaining 42% to be acquired over 5-7 years.
Recommended a final dividend of Rs 3 per equity share (30% on face value of Rs 10) for FY26.
Incorporation of 'Honasa Health Private Limited' on July 7, 2026, to house the B2C nutraceuticals business.
Paid-up equity capital increased to Rs 3,260.24 million following the allotment of 654,422 shares via ESOPs.
👀 What to Watch
Monitor the integration timeline of Fluence Pharma and the revenue contribution from the newly formed nutraceuticals subsidiary in upcoming quarters. Investors should also track the actual cash realization of the Rs 25.53 crore legal award from the UAE-based entity.
Rs 4.43 Cr Dubai Court Judgment Upheld; Honasa Cites Indian Arbitral Award for No Impact
The Cassation Court in Dubai has upheld a previous judgment awarding AED 1.71 million (approx. Rs 4.43 Cr) to RSM General Trading LLC, dismissing appeals from both parties. RSM had sought significantly higher damages of AED 45 million (approx. Rs 117 Cr), which the court categorically rejected. Honasa maintains that this will have no financial impact due to a prior Indian Arbitral Tribunal award (May 2025) which injuncts RSM from Dubai proceedings and requires RSM to indemnify Honasa for any amounts recovered there. The company further argues the Dubai judgment is not binding under Indian law as the original agreement is governed by Indian law.
Confidence: HIGH
What changedThe final appellate court in Dubai has concluded the litigation process in that jurisdiction, upholding a relatively small damage award against Honasa while rejecting RSM's much larger claim.
Why it mattersThe financial liability is immaterial (0.19% of revenue) and is legally hedged by a favorable Indian arbitration award, minimizing the risk of a significant cash outflow.
Award amount: Rs 4,43,12,369Damages sought by RSM: AED 45,000,000Award vs TTM Revenue: ~0.19%Award vs TTM PAT: ~2.27%Indian Arbitral Award Date: May 14, 2025
📅 Short termNeutral impact expected as the award amount is small and the company has a legal counter-strategy in place via Indian arbitration.
📈 Long termLimited; this resolves a legacy distributor dispute and allows management to focus on core business expansion and brand scaling.
⚠ Risk flags
- Potential legal complexity if RSM attempts to enforce the Dubai judgment in Indian courts despite the injunction.
Key Highlights
Dubai Cassation Court upheld an award of AED 1,707,407.06 (approx. Rs 4.43 Cr) to RSM for material and moral damages.
RSM's appeal seeking damages of AED 45,000,000 (approx. Rs 117 Cr) was rejected by the court.
The award amount of Rs 4.43 Cr represents approximately 0.19% of Honasa's TTM revenue of Rs 2,355 Cr.
An Indian Arbitral Tribunal award dated May 14, 2025, already declared RSM must pay Honasa any amount recovered via Dubai court proceedings.
Honasa received the translated judgment on August 07, 2026, following the court's decision on July 29, 2026.
👀 What to Watch
Investors should monitor any potential enforcement actions by RSM in India and how Indian courts reconcile the conflicting Dubai judgment with the existing Indian Arbitral Award.
Honasa Consumer Elevates Nilesh Kotalwar to Chief Marketing Officer
Honasa Consumer Limited has promoted Nilesh Kotalwar to the role of Chief Marketing Officer (CMO) effective August 06, 2026. Kotalwar, an IIM Lucknow alumnus with over 15 years of experience at FMCG leaders like HUL and Godrej, previously served as the company's SVP of Online Revenue for two years. This internal elevation aims to integrate marketing functions across the company's portfolio, which includes Mamaearth and The Derma Co, to support its 20%+ growth target. The move comes as the company maintains a strong 71%+ gross margin profile while expanding its offline presence.
Confidence: HIGH
What changedNilesh Kotalwar has been promoted from Senior Vice President of Online Revenue to the Chief Marketing Officer (CMO) of the company.
Why it mattersFor a digital-first BPC company, the CMO role is critical for brand equity and customer acquisition costs. An internal promotion of a leader with HUL/Godrej pedigree suggests a focus on combining traditional brand-building with digital-first data analytics.
Experience: 15+ yearsTenure at Honasa: 2 yearsTTM Revenue: Rs 2355 CrGross Margin: 71%+Market Cap: Rs 14707 Cr
📅 Short termThe announcement is unlikely to trigger significant price movement as it is an internal promotion ensuring leadership continuity.
📈 Long termThe appointment is structurally important for Honasa's 'House of Brands' strategy, specifically in driving innovation and consumer connection across multiple niche beauty labels.
⚠ Risk flags
- Execution risk in balancing digital-first roots with aggressive offline expansion (Project Neev)
Key Highlights
Nilesh Kotalwar elevated to Chief Marketing Officer effective August 06, 2026
Brings over 15 years of FMCG and eCommerce experience from Hindustan Unilever and Godrej Consumer Products
Previously served 2 years at Honasa as SVP – Online Revenue, driving digital commerce growth
Company manages a portfolio with TTM revenue of Rs 2,355 Cr and 10% operating margins
Focus remains on scaling 'Focus Categories' from 75% to 84-85% of revenue over 4-6 quarters
👀 What to Watch
Investors should monitor the effectiveness of integrated marketing strategies in scaling younger brands like Aqualogica and Dr. Sheth's to match Mamaearth's scale. Watch for any shifts in marketing spend as a percentage of revenue in upcoming quarterly results.
30% YoY Growth Expected in Q1 FY27; Younger Brands Surge 40%+
Honasa Consumer expects a strong start to FY27 with adjusted YoY revenue growth of approximately 30% for Q1. While reported growth is expected in the mid-20s due to Flipkart's revenue recognition policy changes, the underlying momentum remains robust across focus categories. The flagship Mamaearth brand is projected to grow in the high-teens, while younger brands like The Derma Co and Aqualogica are growing significantly faster in the early 40s. Crucially, the company expects to sustain a double-digit operating margin profile, aided by operating leverage from its scaling brands.
Confidence: HIGH
What changedHonasa has provided a preliminary Q1 FY27 update indicating a return to high-growth momentum (30% adjusted) following previous quarters of channel inventory recalibration.
Why it mattersThe update confirms that the multi-brand strategy is working, with younger brands growing twice as fast as the flagship, and that the company is maintaining profitability (double-digit margins) while scaling.
Adjusted YoY Revenue Growth: ~30%Younger Brands Growth: early 40s %Mamaearth Growth: high-teens %Operating Margin Profile: double-digitTTM Revenue: Rs 2355 Cr
📅 Short termThe stock may react positively to the 30% growth projection, which is higher than the company's historical 20%+ growth guidance.
📈 Long termThe structural shift towards a 'house of brands' model is evident, with younger brands providing a significant growth cushion to the mature Mamaearth brand.
⚠ Risk flags
- Accounting-led fluctuations due to marketplace settlement changes
- Execution risks in offline distribution expansion (Project Neev)
Key Highlights
Adjusted YoY revenue growth expected at approximately 30% for Q1 FY27
Younger brands (The Derma Co, Aqualogica, etc.) expected to grow in the early 40s YoY
Flagship brand Mamaearth projected to deliver high-teens YoY growth
Reported YoY growth expected in the mid-20s after adjusting for Flipkart settlement changes
Operating margin profile expected to remain in double digits for the quarter
👀 What to Watch
Investors should monitor the upcoming detailed Q1 FY27 results to see if the double-digit operating margins lead to a significant expansion in PAT, which stood at Rs 69 Cr in the previous quarter. The key execution metric to watch is the continued growth of younger brands as they become a larger portion of the total revenue mix.
Honasa Consumer Wins Favorable Rectification Order; Total Award Increased to ~₹25.54 Crores
Honasa Consumer Limited has received a favorable rectification order in its arbitration against RSMM General Trading LLC, resulting in an upward revision of the final award. The total monetary payout is now approximately AED 9.92 million (around ₹25.54 Crores), primarily driven by a correction in loss of profits from AED 4.34 million to AED 7.32 million. Crucially, the tribunal also ordered RSM to indemnify Honasa against any financial liabilities arising from related Dubai court proceedings. This development provides significant legal clarity and a direct positive impact on the company's potential cash flows.
Key Highlights
Total monetary award increased to AED 9,918,514 (approximately INR 25.54 Crores) following the rectification order.
Loss of profits award revised upward from AED 4.34 million to AED 7.32 million due to computational error correction.
RSM is now liable to pay Honasa damages equivalent to any financial recoveries made against the company in related Dubai court proceedings.
Post-award interest penalties (EIBOR + 2% for AED and SBI PLR + 2% for INR) will apply if the amount is not paid within 30 days.
👀 What to Watch
Investors should view this as a positive legal outcome that strengthens the balance sheet by approximately ₹25.5 Crores. Monitor the actual receipt of funds and any further developments regarding the enforcement of this award against the distributor.
Honasa Consumer Acquires 58% Stake in Fluence Pharma to Enter Nutraceuticals Market
Honasa Consumer Limited has announced the acquisition of a 58% majority stake in Fluence Pharma, marking its strategic entry into the INR 16,000 Crore+ Indian nutraceuticals market. Fluence Pharma is a profitable entity, reporting approximately INR 40 Crore in revenue with a healthy EBITDA margin of over 20% in FY26. The acquisition provides Honasa with access to patented Cyclical Nutrition Therapy (CNT) and a distribution network of over 3,000 dermatologists. This business will be scaled under a newly formed subsidiary, Honasa Health Private Limited, led by industry veteran Dheeraj Nagpal.
Key Highlights
Acquisition of a 58% majority stake in science-backed nutraceutical company Fluence Pharma.
Fluence Pharma reported ~INR 40 Crore revenue and 20%+ EBITDA margins for FY26.
Strategic entry into the high-growth INR 16,000 Crore+ Indian nutraceuticals and 'inside-out' beauty market.
Access to patented Cyclical Nutrition Therapy (CNT) and a network of 3,000+ practicing dermatologists.
Establishment of Honasa Health Private Limited to scale the B2C nutrition portfolio using digital-first expertise.
👀 What to Watch
Investors should view this as a positive move to diversify into high-margin, science-backed health categories that complement the core beauty business. Monitor the integration and scaling of Fluence's clinical products through Honasa's established digital distribution channels.
Honasa to acquire 58% stake in Fluence Pharma for ₹135 Cr EV; enters Nutraceuticals
Honasa Consumer is acquiring a majority 58% stake in Fluence Pharma at an enterprise value of ~₹135 crore, marking its entry into the high-growth nutraceuticals segment. Fluence Pharma specializes in science-led hair and skin supplements with a network of 3,000+ dermatologists and a 20%+ EBITDA margin. Honasa also announced the incorporation of a new subsidiary, Honasa Health Private Limited, to scale these products through B2C channels. The company aims to build this into a ₹500 crore franchise by leveraging its digital distribution expertise alongside Fluence's patented technology.
Key Highlights
Acquisition of 58% stake in Fluence Pharma at ~3.4x FY26 Revenue and ~15x FY26 EBITDA multiples.
Fluence Pharma reported FY25 revenue of ₹37.21 crore and has a strong doctor-led distribution moat.
The remaining 42% stake will be acquired in two tranches over the next 5-7 years.
Incorporation of 'Honasa Health Private Limited' to drive B2C nutraceutical operations.
Strategic access to patented 'Cyclical Nutrition Therapy' and a network of 3,000+ prescribing dermatologists.
👀 What to Watch
Investors should view this as a strategic move to diversify into high-margin health supplements that complement Honasa's existing beauty portfolio. Monitor the execution of the B2C rollout under the new subsidiary, as success here could significantly enhance the company's long-term growth profile.
Honasa Consumer Targets ₹5,500+ Cr Revenue and 15% EBITDA Margin by FY31
Honasa Consumer (Mamaearth) has outlined an ambitious 'FY31 Vision' during its 2026 Investor Day, targeting a revenue of over ₹5,500 Cr, more than doubling its FY26 revenue of ₹2,400 Cr. The company aims to expand its EBITDA margin to 15% by FY31, a 500 bps improvement driven by channel efficiencies, procurement gains, and operating leverage. Strategic goals include scaling Mamaearth to a ₹2,000+ Cr brand and The Derma Co to ₹1,500+ Cr. The roadmap emphasizes 'Honasa 2.0,' which leverages AI-led distribution and product superiority to capture a larger share of the $20B+ Indian BPC market.
Key Highlights
Targeting ₹5,500+ Cr revenue by FY31, up from ₹2,400 Cr in FY26, aiming to be the fastest FMCG to reach ₹5,000 Cr.
Projecting 15% EBITDA margin by FY31, unlocking 500 bps through improved channel mix and operating leverage.
Mamaearth and The Derma Co targeted to reach ₹2,000+ Cr and ₹1,500+ Cr respectively by FY31.
Plans to expand direct offline distribution reach to 300,000+ outlets from the current 120,000.
Introduction of 'Honasa 2.0' strategy focusing on AI-agent led marketing, distribution, and R&D superiority.
👀 What to Watch
Investors should view this as a strong long-term growth signal, though execution of the 500 bps margin expansion and scaling of younger brands remains critical. Monitor quarterly progress on direct distribution reach and the growth of non-Mamaearth brands as key performance indicators.
Honasa Consumer Q4 FY26 Revenue Up 28%, Declares Maiden Dividend of INR 3 Per Share
Honasa Consumer reported a robust Q4 FY26 with revenue growing 28% Y-o-Y to INR 682 crores and EBITDA scaling 2.5x to INR 77 crores. The company achieved a full-year PAT of INR 200 crores and rewarded shareholders with its first-ever dividend of INR 3 per share, representing a 50% payout ratio. Growth was primarily volume-driven, with focus categories growing at 35% and the newly acquired Reginald brand doubling its revenue to cross the INR 100 crore ARR mark. Management remains confident in maintaining a double-digit CAGR for the flagship Mamaearth brand while expanding into the nutraceuticals space.
Key Highlights
Q4 FY26 revenue reached INR 682 crores with 28% Y-o-Y growth and 71.4% gross margins.
EBITDA for the quarter surged 2.5x to INR 77 crores, achieving an 11.3% margin.
Declared maiden dividend of INR 3 per share, totaling a cash payout of approximately INR 98 crores.
Portfolio now includes 6 brands with an Annual Run Rate (ARR) exceeding INR 100 crores.
Mamaearth distribution currently at 200,000 outlets with a target to reach 500,000 in 3-5 years.
👀 What to Watch
Investors should take note of the company's transition to a dividend-paying entity and its consistent margin expansion. The successful scaling of younger brands like The Derma Co and Reginald provides a strong growth runway beyond the flagship Mamaearth brand.
Honasa Consumer FY26 PAT Surges 176% to ₹1,908M; Announces Maiden Dividend of ₹3
Honasa Consumer Limited (Mamaearth) reported a robust performance for the financial year ended March 31, 2026, with standalone Profit After Tax (PAT) jumping 176% YoY to ₹1,908.27 million. Revenue from operations grew 14% to ₹23,054.12 million, driven by expansion across its beauty and personal care portfolio. The board has recommended its first-ever dividend of ₹3 per share, signaling confidence in cash flow generation. Additionally, the company strengthened its leadership by appointing three new Senior Management Personnel to lead product, data, and revenue growth.
Key Highlights
Annual standalone Profit After Tax (PAT) increased to ₹1,908.27 million in FY26 from ₹689.70 million in FY25.
Revenue from operations for FY26 rose to ₹23,054.12 million compared to ₹20,218.43 million in the previous year.
Recommended a maiden final dividend of ₹3 per equity share (30% of face value of ₹10).
Q4 FY26 PAT stood at ₹644.73 million, a significant jump from ₹246.14 million in the same quarter last year.
Utilized ₹3,152.66 million of IPO proceeds as of March 31, 2026, primarily for brand awareness and capital expenditure.
👀 What to Watch
The strong bottom-line growth and maiden dividend declaration indicate a positive shift toward sustainable profitability and shareholder returns. Investors should maintain a positive outlook while monitoring the impact of the newly appointed senior management on offline and online revenue scaling.
Honasa Consumer FY26 PAT Surges 176% to ₹1,908M; Announces Maiden ₹3 Dividend
Honasa Consumer Limited (Mamaearth) reported a robust financial performance for FY26, with annual revenue growing 14% to ₹23,054 million. The company's net profit witnessed a massive 176% year-on-year increase, reaching ₹1,908 million, reflecting significant margin expansion. In a first for the company, the board has recommended a maiden final dividend of ₹3 per share. Furthermore, the leadership team has been strengthened with three new senior appointments across product, data, and revenue functions to drive the next phase of growth.
Key Highlights
Annual Revenue from operations increased to ₹23,054.12 million in FY26 compared to ₹20,218.43 million in FY25.
Net Profit (PAT) for the full year jumped 176% YoY to ₹1,908.27 million from ₹689.70 million.
Recommended a maiden final dividend of ₹3 per equity share (30% of face value of ₹10).
Appointed three new Senior Management Personnel: Vipul Maheshwari (EVP - Product and Data), Nishchay Bahl (SVP - Offline Revenue), and Nilesh Kotalwar (SVP - Online Revenue).
Utilized ₹3,152.66 million of IPO proceeds as of March 31, 2026, primarily for brand awareness and expansion.
👀 What to Watch
The strong bottom-line growth and maiden dividend signal a positive shift toward sustainable profitability; investors should monitor how the new leadership scales the offline revenue vertical.
Honasa Consumer Q4 FY26 PAT Jumps 175% YoY; Announces Maiden Dividend of ₹3 Per Share
Honasa Consumer reported its highest-ever quarterly revenue of ₹682 crore in Q4 FY26, marking a 28% YoY growth on a like-for-like basis. The company demonstrated significant operating leverage with Q4 EBITDA surging 185% YoY to ₹77 crore and PAT rising 175% to ₹69 crore. For the full year FY26, revenue reached ₹2,479 crore with a volume-led growth of 23%. Notably, the board recommended its first-ever dividend of ₹3 per share, reflecting a 51.2% payout of standalone PAT.
Key Highlights
Q4 FY26 PAT surged 175%+ YoY to ₹69 Cr with a 10.2% net profit margin.
Board recommended maiden dividend of ₹3 per share (30% of face value), totaling ~₹98 Cr payout.
Underlying Volume Growth (UVG) stood strong at 30% for Q4 and 23% for the full year FY26.
Younger brands grew at 40%+ YoY, with newly consolidated Reginald Men hitting an ARR of ₹100 Cr+.
Gross profit margins improved by 69 bps YoY to 71.4% in Q4 FY26 despite revenue recognition changes.
👀 What to Watch
Investors should take confidence in the maiden dividend and strong volume-led growth as indicators of business maturity and cash flow stability. The successful scaling of younger brands and expansion into nutraceuticals provide a clear roadmap for sustained growth.
Honasa Q4 FY26: PAT Doubles to ₹69 Cr, Revenue Up 28% YoY; Maiden ₹3 Dividend Announced
Honasa Consumer reported its highest-ever quarterly revenue of ₹682 Cr in Q4 FY26, marking a 28% YoY growth and the third consecutive quarter of 20%+ growth. Profitability surged as PAT more than doubled to ₹69 Cr for the quarter, bringing the annual PAT to ₹200 Cr. The company's younger brands grew by over 40%, and the newly consolidated Reginald Men brand hit an ARR of ₹100 Cr+. Additionally, the board recommended its first-ever dividend of ₹3 per share, signaling strong cash flow and management confidence.
Key Highlights
Q4 FY26 revenue reached a record ₹682 Cr, representing a 28% YoY increase.
Quarterly PAT more than doubled YoY to ₹69 Cr, with full-year FY26 PAT hitting ₹200 Cr.
Board recommended a maiden final dividend of ₹3 per equity share, representing a 51.2% payout of standalone PAT.
Younger brands grew 40%+ YoY in FY26, while Reginald Men achieved an ARR of ₹100 Cr+ in its first quarter of consolidation.
Offline distribution reached ~1.2 lakh outlets billed directly, supporting a 35%+ growth in focus categories.
👀 What to Watch
Investors should consider this a strong performance indicating successful scaling of the 'House of Brands' strategy; monitor the sustainability of the 20% growth trajectory and the margin profile of younger brands.
Honasa Consumer FY26 PAT Surges 176% to ₹1,908M; Announces Maiden ₹3 Dividend
Honasa Consumer Limited (Mamaearth) reported a robust financial performance for FY26, with annual revenue from operations growing 14% to ₹23,054.12 million. The company's Profit After Tax (PAT) saw a massive jump of 176%, reaching ₹1,908.27 million compared to ₹689.70 million in the previous fiscal year. In a significant milestone, the board has recommended its first-ever dividend of ₹3 per share. The company also strengthened its leadership by appointing three new senior executives to lead product, data, and revenue functions.
Key Highlights
FY26 Revenue from operations increased to ₹23,054.12 million from ₹20,218.43 million in FY25.
Net Profit (PAT) for the full year surged 176% YoY to ₹1,908.27 million.
Recommended a maiden final dividend of ₹3 per equity share (30% of face value of ₹10).
Q4 FY26 PAT stood at ₹644.73 million, more than doubling from ₹246.14 million in the same quarter last year.
Appointed new senior management: Vipul Maheshwari (EVP - Product & Data), Nishchay Bahl (SVP - Offline Revenue), and Nilesh Kotalwar (SVP - Online Revenue).
👀 What to Watch
The maiden dividend and strong profit growth signal a maturing business model with improved cash flow; investors should maintain a positive outlook while monitoring the impact of new leadership on revenue scaling.
